Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152332 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants
A Phase 1 study of Healthy, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT02152332 is a Phase 1 study of Healthy that has completed, run by Janssen Research & Development. The registered enrollment target is 64 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02152332, a Phase 1 study of Healthy, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effects of JNJ-54861911 on the QT/QTc intervals in healthy participants, when administered at therapeutic (50 milligram \[mg\] once-daily) and supratherapeutic (150 mg once-daily) doses for 7 days.
Conditions Studied
Interventions
- DRUG Moxifloxacin
- DRUG JNJ-54861911-Therapeutic Dose
- DRUG JNJ-54861911 - Supratherapeutic Dose
- DRUG JNJ-54861911-Matched Placebo
- DRUG Moxifloxacin Matched Placebo
Study Locations (1)
Arizona
- - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02152332
The ClinicalTrials.gov registry entry for NCT02152332 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which Moxifloxacin is the first listed.
NCT02152332 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT02152332 about?
NCT02152332 is a clinical study titled "A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants". The purpose of this study is to evaluate the effects of JNJ-54861911 on the QT/QTc intervals in healthy participants, when administered at therapeutic (50 milligram \[mg\] once-daily) and supratherapeutic (150 mg once-daily) doses for 7 days.
What is the current status of trial NCT02152332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2014-07. Estimated completion is 2014-10.
What conditions does trial NCT02152332 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02152332?
The interventions under investigation include: Moxifloxacin (DRUG), JNJ-54861911-Therapeutic Dose (DRUG), JNJ-54861911 - Supratherapeutic Dose (DRUG), JNJ-54861911-Matched Placebo (DRUG), Moxifloxacin Matched Placebo (DRUG).
Who is sponsoring clinical trial NCT02152332?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02152332 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.